Fasting C-peptide

There are 12 papers on fasting C-peptide in aging research: 6 trials and 5 observational studies in people.

Biomarker

12 papers study it23 more mention it9 findings

3 new papers in 30 daysSee all 35 papers on fasting C-peptide

“Logistic regression revealed that knee extension strength, fasting C-peptide (F-CPR) level and dorsiflexion strength were independent predictors of falls.”
Exploratory analysis using machine learning of predictive factors for falls in type 2 diabetesScientific reports2022doi:10.1038/s41598-022-15224-4
  • Human trial6
  • Humans5

Interventions

5

Tirzepatide

downin humans1

1 study
  1. Tirzepatide decreases fasting C-peptide in humans (compared with an increase of C-peptide with semaglutide 1 mg) (5.2%-6.0% reduction with tirzepatide 10 and 15 mg; 3.3% increase with semaglutide 1 mg).

    “Tirzepatide 10 and 15 mg resulted in a significant reduction in both fasting C-peptide (5.2%-6.0%)”

    Human trialcompared with an increase of C-peptide with semaglutide 1 mg10 and 15 mg once weekly40 weeks

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

    The Journal of clinical endocrinology and metabolism

  2. Tirzepatide decreases fasting C-peptide in humans (5.2%-6.0% compared with the observed increase with semaglutide 1 mg (3.3%)).

    “Greater and significant reductions in fasting C-peptide were seen with tirzepatide 10 and 15 mg (5.2%-6.0%) compared with the observed increase with semaglutide 1 mg (3.3%) (P <.05) at week 40.”

    Human trial40-week

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

    The Journal of clinical endocrinology and metabolism

More on Tirzepatide

GLP-1 receptor agonists

upin humans1

1 study
  1. GLP-1 receptor agonists are linked with higher fasting C-peptide in humans (combined with basal insulin, after glucose profiles improved) (from 0.65±0.36 to 1.03±0.55 ng/mL).

    “Soon after daily glucose profiles were improved, F-CPR was 1.03±0.55 (0.30~1.94) ng/mL.”

    Humanscombined with basal insulin, after glucose profiles improvedfemalesn = 7

    21-PUB: GLP-1 Receptor Agonist–Based Therapy in Early Type 1 Diabetes

    Diabetes

More on GLP-1 receptor agonists

Liraglutide plus metformin

upin humans1

1 study
  1. Liraglutide plus metformin is linked with higher fasting C-peptide in humans (compared with liraglutide plus acarbose).

    “The fasting C-peptide and 2-h postprandial C-peptide levels in group A after treatment were higher than those in group B (P<0.05).”

    Humanscompared with liraglutide plus acarbosen = 88

    Effect of liraglutide combined with metformin or acarbose on glucose control in type 2 diabetes mellitus and risk factors of gastrointestinal adverse reactions

    American journal of translational research

More on Liraglutide plus metformin

Vildagliptin

upin humans1

1 study
  1. Vildagliptin increases fasting C-peptide in humans.

    “which increased fasting C-peptide level greater than the other two drugs”

    Human trialn = 30

    A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment

    Life sciences

More on Vildagliptin

Sitagliptin

upin humans1

1 study
  1. Sitagliptin increases fasting C-peptide in humans (combined with CSII versus CSII alone).

    “FC-P (Fasting c-peptide) levels in group C and group B were significantly higher than those in group A”

    Human trialcombined with CSII versus CSII alonetwo weeks

    Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus

    Journal of biological regulators and homeostatic agents

More on Sitagliptin

Associations

3

Glycemic response

upin humans1OR 2.58

1 study
  1. Fasting C-peptide predicts glycemic response in humans (Type 2 diabetes; response defined as an HbA1c reduction of at least 1.0 percentage point) (Adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001; AUC = 0.805; exploratory cut-off 2.33 ng/mL).

    “Baseline C-peptide independently predicted glycemic response (adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001)”

    HumansType 2 diabetes; response defined as an HbA1c reduction of at least 1.0 percentage pointMean follow-up of 156 daysn = 196

    C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide

    Medicina (Kaunas, Lithuania)

DPP-4 inhibitors

upin humans1

1 study
  1. DPP-4 inhibitors are associated with fasting C-peptide in humans (Type 2 diabetes; compared with SGLT2 inhibitor therapy) (Changes: 0.18 ± 0.44 vs. 0.03 ± 0.38 ng/mL; between-group p = 0.010; adjusted β = 0.149, p = 0.013).

    “DPP-4 inhibitor therapy remained independently associated with higher follow-up C-peptide (adjusted β = 0.149; p = 0.013).”

    HumansType 2 diabetes; compared with SGLT2 inhibitor therapyMean follow-up of 156 daysn = 196

    C-Peptide Changes and Glycemic Response During DPP-4 Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: The Role of Baseline C-Peptide

    Medicina (Kaunas, Lithuania)

More on DPP-4 inhibitors

Falls

upin humans1

1 study
  1. Fasting C-peptide predicts falls in humans (type 2 diabetes).

    “Logistic regression revealed that knee extension strength, fasting C-peptide (F-CPR) level and dorsiflexion strength were independent predictors of falls.”

    Humanstype 2 diabetesone year after dischargen = 226

    Exploratory analysis using machine learning of predictive factors for falls in type 2 diabetes

    Scientific reports

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 1Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 5Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 2Nov 2026: 117 papers in 12 months

See all 35 papers on fasting C-peptide